Understanding how puberty affects kidney health in youth with diabetes
Official title: PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress
Run by Seattle Children's Hospital · NCT05008276 · Data updated 2026-11-12
This study looks at how puberty affects kidney health in teenagers with type 2 diabetes and obesity to see if the changes during this time can harm their kidneys.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 8 Years to 14 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Seattle Children's Hospital Academic / other |
| Locations | 2 sites (Aurora, Colorado and 1 other locations) |
| Status | Recruiting |
| Started | September 27, 2021 |
| Main results expected | December 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | March 24, 2025 |
| Trial ID | NCT05008276 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adolescents with type 2 diabetes or prediabetes who are obese and have specific HbA1c levels.
✕Probably not a fit
Patients with a history of chronic kidney disease or acute kidney injury may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the relationship between puberty and kidney health in adolescents with type 2 diabetes and obesity. It aims to understand how the physiological changes during puberty may lead to kidney injury, particularly focusing on the concept of kidney hypoxia. The study will utilize functional magnetic resonance imaging (MRI) and other assessments over a five-year period to evaluate the impact of these changes on kidney function. By identifying the mechanisms linking puberty and diabetic kidney disease, the research seeks to inform strategies for preserving kidney health in affected youth.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing kidney disease in adolescents with type 2 diabetes.
How similar studies have gone: While there is emerging data on the impact of puberty on kidney health, this specific approach to studying the relationship in youth with diabetes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * HbA1c ≥6.0% for untreated high-risk group * BMI ≥ 85th %ile for high-risk group * Normal HbA1c ≤5.6% for control group * Type 1 diabetes (T1D) Antibody negative Exclusion Criteria: * History of Chronic kidney disease (CKD) or acute kidney injury (AKI) * Metabolic disorder prohibiting safe fasting * Iodine or penicillin allergy * Pregnancy * Thrombophilia * MRI contraindications * Hormone therapy
Where it's running
-
Children's Hospital Colorado
Aurora, Colorado, United States Recruiting -
Seattle Children's Hospital
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Petter Bjornstad, MD — University of Washington - Medicine Diabetes Institute
- Study coordinator: Petter Bjornstad, MD
- Email: pettermb@uw.edu
- Phone: (206) 616 3543
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Acupuncture plus vitamin B12 for diabetic heart nerve damage
This study tests whether adding acupuncture to standard care and vitamin B12 can help adults with type 2 diabetes who have damaged the nerves that control the heart.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes
This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.
-
Single-dose PK study of HRS-4729 in adults with and without kidney impairment
This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.
-
Once-daily ASC30 to See if it helps adults with obesity or overweight and Type 2 diabetes
This study tests three daily doses of ASC30 against placebo in adults who are overweight or obese and have Type 2 diabetes to see if it helps with weight loss and safety over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.